Targeting tumor extracellular matrix activates the tumor-draining lymph nodes

Alexander J. Najibi, Ting Yu Shih, David K.Y. Zhang, Junzhe Lou, Miguel C. Sobral, Hua Wang, Maxence O. Dellacherie, Kwasi Adu-Berchie, David J. Mooney

Research output: Contribution to journalArticlepeer-review


Disruption of the tumor extracellular matrix (ECM) may alter immune cell infiltration into the tumor and antitumor T cell priming in the tumor-draining lymph nodes (tdLNs). Here, we explore how intratumoral enzyme treatment (ET) of B16 melanoma tumors with ECM-depleting enzyme hyaluronidase alters adaptive and innate immune populations, including T cells, DCs, and macrophages, in the tumors and tdLNs. ET increased CD103+ DC abundance in the tdLNs, as well as antigen presentation of a model tumor antigen ovalbumin (OVA), eliciting local OVA-specific CD8+ T cell responses. Delivered in combination with a distant cryogel-based cancer vaccine, ET increased the systemic antigen-specific CD8+ T cell response. By enhancing activity within the tdLN, ET may broadly support immunotherapies in generating tumor-specific immunity.

Original languageEnglish (US)
Pages (from-to)2957-2968
Number of pages12
JournalCancer Immunology, Immunotherapy
Issue number12
StatePublished - Dec 2022


  • Adaptive immunity
  • Cancer vaccine
  • Tumor extracellular matrix
  • Tumor-draining lymph nodes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Targeting tumor extracellular matrix activates the tumor-draining lymph nodes'. Together they form a unique fingerprint.

Cite this